Embolic Materials' Comparison in Meningeal Artery Embolization for Chronic Subdural Hematomas: Multicenter Propensity Score-Matched Analysis of 1070 Cases.
Journal
Neurosurgery
ISSN: 1524-4040
Titre abrégé: Neurosurgery
Pays: United States
ID NLM: 7802914
Informations de publication
Date de publication:
17 Oct 2024
17 Oct 2024
Historique:
received:
24
05
2024
accepted:
23
08
2024
medline:
29
10
2024
pubmed:
29
10
2024
entrez:
29
10
2024
Statut:
aheadofprint
Résumé
Multiple preferences exist for embolic materials selection in middle meningeal artery embolization (MMAE) for chronic subdural hematoma with limited comparative literature data. Herein, we compare different embolic materials. Consecutive patients undergoing MMAE for chronic subdural hematoma at 14 North-American centers (2018-2023) were classified into 3 groups: (a) particles, (b) Onyx, (c) n-butyl cyanoacrylate (n-BCA). The end points were unplanned rescue surgery, radiographic success (≥50% reduction in hematoma thickness at last imaging "minimum of 2 weeks"), and major complications. Initial unmatched analysis compared the 3 groups; subsequent propensity score matching (PSM) compared particles vs liquid embolics (groups b and c combined). Additional subgroup PSM analyses compared particles vs Onyx, particles vs n-BCA, and Onyx vs n-BCA. All matched analyses controlled for age, sex, concurrent surgery, previous surgery, hematoma thickness, midline shift, pretreatment antithrombotics, and baseline modified Rankin Scale. Eight hundred and seventy-two patients (median age 73 years, 72.9% males) underwent 1070 MMAE procedures. Onyx was most used (41.4%), then particles (40.3%) and n-BCA (15.5%). Surgical rescue rates were comparable between particles, Onyx, and n-BCA (9.8% vs 7% vs 11.7%, respectively, P = .14). Similarly, radiographic success (78.8% vs 79.3% vs 77.4%; P = .91) and major complications (2.4% vs 2.3% vs 2.5%; P = .83) were comparable. The PSM comparing particles vs liquid generated 128 matched pairs; general anesthesia and bilateral procedures were significantly higher in particles (37.8% vs 21.3%; P = .004 and 39.8% vs 27.3%; P = .034, respectively). No differences in surgical rescue, radiographic improvement, or major complications were noted (P > .05). Concurrently, PSM comparing particles vs Onyx, particles vs n-BCA, and Onyx vs n-BCA, resulted in 112, 42, and 40 matched pairs, respectively, without differences in surgical rescue, radiographic success, or major complications (P > .05). We found no differences in radiological improvement, surgical rescue, or major complications between embolic materials in MMAE. Current randomized trials are exclusively using liquid embolics, and these data suggest that future trials involving particles are likely to produce similar outcomes.
Sections du résumé
BACKGROUND AND OBJECTIVES
OBJECTIVE
Multiple preferences exist for embolic materials selection in middle meningeal artery embolization (MMAE) for chronic subdural hematoma with limited comparative literature data. Herein, we compare different embolic materials.
METHODS
METHODS
Consecutive patients undergoing MMAE for chronic subdural hematoma at 14 North-American centers (2018-2023) were classified into 3 groups: (a) particles, (b) Onyx, (c) n-butyl cyanoacrylate (n-BCA). The end points were unplanned rescue surgery, radiographic success (≥50% reduction in hematoma thickness at last imaging "minimum of 2 weeks"), and major complications. Initial unmatched analysis compared the 3 groups; subsequent propensity score matching (PSM) compared particles vs liquid embolics (groups b and c combined). Additional subgroup PSM analyses compared particles vs Onyx, particles vs n-BCA, and Onyx vs n-BCA. All matched analyses controlled for age, sex, concurrent surgery, previous surgery, hematoma thickness, midline shift, pretreatment antithrombotics, and baseline modified Rankin Scale.
RESULTS
RESULTS
Eight hundred and seventy-two patients (median age 73 years, 72.9% males) underwent 1070 MMAE procedures. Onyx was most used (41.4%), then particles (40.3%) and n-BCA (15.5%). Surgical rescue rates were comparable between particles, Onyx, and n-BCA (9.8% vs 7% vs 11.7%, respectively, P = .14). Similarly, radiographic success (78.8% vs 79.3% vs 77.4%; P = .91) and major complications (2.4% vs 2.3% vs 2.5%; P = .83) were comparable. The PSM comparing particles vs liquid generated 128 matched pairs; general anesthesia and bilateral procedures were significantly higher in particles (37.8% vs 21.3%; P = .004 and 39.8% vs 27.3%; P = .034, respectively). No differences in surgical rescue, radiographic improvement, or major complications were noted (P > .05). Concurrently, PSM comparing particles vs Onyx, particles vs n-BCA, and Onyx vs n-BCA, resulted in 112, 42, and 40 matched pairs, respectively, without differences in surgical rescue, radiographic success, or major complications (P > .05).
CONCLUSION
CONCLUSIONS
We found no differences in radiological improvement, surgical rescue, or major complications between embolic materials in MMAE. Current randomized trials are exclusively using liquid embolics, and these data suggest that future trials involving particles are likely to produce similar outcomes.
Identifiants
pubmed: 39471085
doi: 10.1227/neu.0000000000003218
pii: 00006123-990000000-01391
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © Congress of Neurological Surgeons 2024. All rights reserved.
Références
Neifert SN, Chaman EK, Hardigan T, et al. Increases in subdural hematoma with an aging population-the future of american cerebrovascular disease. World Neurosurg. 2020;141:e166-e174.
Balser D, Farooq S, Mehmood T, Reyes M, Samadani U. Actual and projected incidence rates for chronic subdural hematomas in United States Veterans Administration and civilian populations. J Neurosurg. 2015;123(5):1209-1215.
Baechli H, Nordmann A, Bucher HC, Gratzl O. Demographics and prevalent risk factors of chronic subdural haematoma: results of a large single-center cohort study. Neurosurg Rev. 2004;27(4):263-266.
Rust T, Kiemer N, Erasmus A. Chronic subdural haematomas and anticoagulation or anti-thrombotic therapy. J Clin Neurosci. 2006;13(8):823-827.
Rudy RF, Catapano JS, Jadhav AP, Albuquerque FC, Ducruet AF. Middle meningeal artery embolization to treat chronic subdural hematoma. Stroke Vasc Interv Neurol. 2023;3(1):e000490.
Takizawa K, Sorimachi T, Ishizaka H, et al. Enlargement of the middle meningeal artery on MR angiography in chronic subdural hematoma. J Neurosurg. 2016;124(6):1679-1683.
Foreman P, Goren O, Griessenauer CJ, Dalal SS, Weiner G, Schirmer CM. Middle meningeal artery embolization for chronic subdural hematomas: cautious optimism for a challenging pathology. World Neurosurg. 2019;126:528-529.
Tanaka T, Kaimori M. Histological study of vascular structure between the dura mater and the outer membrane in chronic subdural hematoma in an adult. No Shinkei Geka. 1999;27(5):431-436.
Ortiz M, Belton P, Burton M, Litofsky NS. Subdural drain versus subdural evacuating port system for the treatment of nonacute subdural hematomas: a single-center retrospective cohort study. World Neurosurg. 2020;139:e355-e362.
Santarius T, Kirkpatrick PJ, Ganesan D, et al. Use of drains versus no drains after burr-hole evacuation of chronic subdural haematoma: a randomised controlled trial. Lancet. 2009;374(9695):1067-1073.
Weigel R, Schmiedek P, Krauss JK. Outcome of contemporary surgery for chronic subdural haematoma: evidence based review. J Neurol Neurosurg Psychiatry. 2003;74(7):937-943.
Mehta V, Harward SC, Sankey EW, Nayar G, Codd PJ. Evidence based diagnosis and management of chronic subdural hematoma: a review of the literature. J Clin Neurosci. 2018;50:7-15.
Kolias AG, Chari A, Santarius T, Hutchinson PJ. Chronic subdural haematoma: modern management and emerging therapies. Nat Rev Neurol. 2014;10(10):570-578.
Ivamoto HS, Lemos HP Jr., Atallah AN. Surgical treatments for chronic subdural hematomas: a comprehensive systematic review. World Neurosurg. 2016;86:399-418.
Soleman J, Lutz K, Schaedelin S, et al. Subperiosteal vs subdural drain after burr-hole drainage of chronic subdural hematoma: a randomized clinical trial (cSDH-Drain-Trial). Neurosurgery. 2019;85(5):e825-e834.
Ironside N, Nguyen C, Do Q, et al. Middle meningeal artery embolization for chronic subdural hematoma: a systematic review and meta-analysis. J Neurointerv Surg. 2021;13(10):951-957.
Ishihara H, Ishihara S, Kohyama S, et al. Experience in endovascular treatment of recurrent chronic subdural hematoma. Interv Neuroradiol. 2007;13(Suppl 1):141-144.
Ban SP, Hwang G, Byoun HS, et al. Middle meningeal artery embolization for chronic subdural hematoma. Radiology. 2018;286(3):992-999.
Kan P, Maragkos GA, Srivatsan A, et al. Middle meningeal artery embolization for chronic subdural hematoma: a multi-center experience of 154 consecutive embolizations. Neurosurgery. 2021;88(2):268-277.
Kim E. Embolization therapy for refractory hemorrhage in patients with chronic subdural hematomas. World Neurosurg. 2017;101:520-527.
Mino M, Nishimura S, Hori E, et al. Efficacy of middle meningeal artery embolization in the treatment of refractory chronic subdural hematoma. Surg Neurol Int. 2010;1:78.
Rajah GB, Waqas M, Dossani RH, et al. Transradial middle meningeal artery embolization for chronic subdural hematoma using Onyx: case series. J Neurointerv Surg. 2020;12(12):1214-1218.
Joyce E, Bounajem MT, Scoville J, et al. Middle meningeal artery embolization treatment of nonacute subdural hematomas in the elderly: a multiinstitutional experience of 151 cases. Neurosurg Focus. 2020;49(4):E5.
Waqas M, Vakhari K, Weimer PV, Hashmi E, Davies JM, Siddiqui AH. Safety and effectiveness of embolization for chronic subdural hematoma: systematic review and case series. World Neurosurg. 2019;126:228-236.
Salem MM, Kuybu O, Nguyen Hoang A, et al. Middle meningeal artery embolization for chronic subdural hematoma: predictors of clinical and radiographic failure from 636 embolizations. Radiology. 2023;307(4):e222045.
Salah WK, Baker C, Scoville JP, et al. Middle meningeal artery embolization as a perioperative adjunct to surgical evacuation of nonacute subdural hematomas: an multicenter analysis of safety and efficacy. Interv Neuroradiol. 2023:159101992311626.
Salah WK, Findlay MC, Baker CM, et al. The influence of coagulopathy on radiographic and clinical outcomes in patients undergoing middle meningeal artery embolization as standalone treatment for non-acute subdural hematomas. J Neurotrauma. 2024;41(11-12):1375-1383.
Salem MM, Sioutas GS, Khalife J, et al. General versus nongeneral anesthesia for middle meningeal artery embolization for chronic subdural hematomas: multicenter propensity score matched study. Neurosurgery. 2024.
Chen H, Salem MM, Colasurdo M, et al. Standalone middle meningeal artery embolization versus middle meningeal artery embolization with concurrent surgical evacuation for chronic subdural hematomas: a multicenter propensity score matched analysis of clinical and radiographic outcomes. J Neurointerv Surg. 2023:jnis-2023-020907.
Salem MM, Sioutas GS, Gajjar A, et al. Femoral versus radial access for middle meningeal artery embolization for chronic subdural hematomas: multicenter propensity score matched study. J Neurointerv Surg. 2024:jnis-2024-021880.
Shehabeldin M, Amllay A, Jabre R, et al. Onyx versus particles for middle meningeal artery embolization in chronic subdural hematoma. Neurosurgery. 2023;92(5):979-985.
Scoville JP, Joyce E, A Tonetti D, et al. Radiographic and clinical outcomes with particle or liquid embolic agents for middle meningeal artery embolization of nonacute subdural hematomas. Interv Neuroradiol. 2023;29(6):683-690.
Ku JC, Dmytriw AA, Essibayi MA, et al. Embolic agent choice in middle meningeal artery embolization as primary or adjunct treatment for chronic subdural hematoma: a systematic review and meta-analysis. AJNR Am J Neuroradiol. 2023;44(3):297-302.
Tudor T, Capone S, Vivanco‐Suarez J, et al. Middle meningeal artery embolization for chronic subdural hematoma: a review of established and emerging embolic agents. Stroke: Vasc Interv Neurol. 2024;4(1):e000906.
Fiorella D, Arthur AS. Middle meningeal artery embolization for the management of chronic subdural hematoma: what a difference a few years make. J Neurointerv Surg. 2023;15(6):515-516.
Shapiro M, Walker M, Carroll KT, et al. Neuroanatomy of cranial dural vessels: implications for subdural hematoma embolization. J Neurointerv Surg. 2021;13(5):471-477.
Levitt MR, Hirsch JA, Chen M. Middle meningeal artery embolization for chronic subdural hematoma: an effective treatment with a bright future. J Neurointerv Surg. 2024;16(4):329-330.